ecteinascidin 743
|
|
|
- CAS-Nr.
- 114899-77-3
- Englisch Name:
- ecteinascidin 743
- Synonyma:
- Trabectedin;ET-743;Yondelis;Ecteinascidin;NSC-684766;NSC 648766;ASMF Filed;cteinascidin;ecteinascidin 743;Trabectedin, >95%
- CBNumber:
- CB31364731
- Summenformel:
- C39H43N3O11S
- Molgewicht:
- 761.84
- MOL-Datei:
- 114899-77-3.mol
|
ecteinascidin 743 Eigenschaften
- Schmelzpunkt:
- >143°C (dec.)
- alpha
- D25 +114° (c = 0.1 in methanol)
- Dichte
- 1.55±0.1 g/cm3 (20 ºC 760 Torr)
- storage temp.
- -20°C Freezer, Under inert atmosphere
- L?slichkeit
- Chloroform (Slightly), Methanol (Slightly)
- pka
- 9.73±0.40(Predicted)
- Aggregatzustand
- Solid
- Farbe
- Light Yellow to Yellow
- Optische Aktivit?t
- -53.824.5 (CHCl3)
- InChIKey
- PKVRCIRHQMSYJX-HAHYLZASNA-N
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
 
|
| Alarmwort |
Achtung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H300 |
Lebensgefahr bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 2 |
Achtung |
![GHS hazard pictograms]() src="/GHS06.jpg" width="20" height="20" /> |
P264, P270, P301+P310, P321, P330,P405, P501 |
| H312 |
Gesundheitssch?dlich bei Hautkontakt. |
Akute Toxizit?t dermal |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P280,P302+P352, P312, P322, P363,P501 |
| H332 |
Gesundheitssch?dlich bei Einatmen. |
Akute Toxizit?t inhalativ |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P261, P271, P304+P340, P312 |
| H341 |
Kann vermutlich genetische Defekte verursachen. |
Keimzellmutagenit?t |
Kategorie 2 |
Warnung |
|
P201,P202, P281, P308+P313, P405,P501 |
| H361 |
Kann vermutlich die Fruchtbarkeit beeintr?chtigen oder das Kind im Mutterleib sch?digen. |
Reproduktionstoxizit?t |
Kategorie 2 |
Warnung |
|
P201, P202, P281, P308+P313, P405,P501 |
| H373 |
Kann die Organe sch?digen bei l?ngerer oder wiederholter Exposition. |
Spezifische Zielorgan-Toxizit?t (wiederholte Exposition) |
Kategorie 2 |
Warnung |
|
P260, P314, P501 |
|
| Sicherheit |
| P201 |
Vor Gebrauch besondere Anweisungen einholen. |
| P202 |
Vor Gebrauch alle Sicherheitshinweise lesen und verstehen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
| P281 |
Vorgeschriebene pers?nliche Schutzausrüstung verwenden. |
| P301+P310 |
BEI VERSCHLUCKEN: Sofort GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
| P308+P313 |
BEI Exposition oder falls betroffen: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
| P321 |
Besondere Behandlung |
| P330 |
Mund ausspülen. |
| P405 |
Unter Verschluss aufbewahren. |
| P501 |
Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
ecteinascidin 743 Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Trabectedin is a marine natural product derived from the tunicate
Ecteinascidia turbinate. With its demonstrated in vitro and in vivo activity against
a range of solid tumor cell lines, human xenografts and tumor explants, this
antineoplastic agent has been developed and launched for the treatment of
advanced STS after failure of first-line therapy with anthracyclines or ifosfamide
or in patients who are unsuited to receive these agents. Its proposed mechanism
of action involves binding to the N2 position of guanine in the minor groove
demonstrating a preference for sequences containing 5′-PuGC and 5′-PyGG
motifs. Subsequent alkylation of DNA, via an iminium intermediate generated
from an intra-molecular acid-catalyzed activation and dehydration of the
carbinolamine, induces a curvature of the DNA toward the major groove that
ultimately disrupts the binding of transcription factors involved in cell
proliferation. Evaluation of trabectedin against the National Cancer Institute’s
human in vitro cell line panel, including melanoma, non-small-cell lung, ovarian,
renal, prostate, and breast cancer, demonstrated potencies ranging from 1 pM to
10 nM.
Definition
ChEBI: A tetrahydroisoquinoline alkaloid obtained from a Caribbean tunicate Ecteinascidia turbinata. Used for the treatment of soft tissue sarcoma and relapsed ovarian cancer.
Nebenwirkungen
The most common adverse events included nausea, fatigue, vomiting, anorexia, neutropenia, and increases in aspartate aminotransferase and alanine aminotransferase liver enzymes. To combat the nausea and vomiting, all patients must receive 20mg of dexamethasone intravenously before the trabectedin infusion. Not only does this pretreatment have an antiemetic effect, it also appears to offer a hepatoprotective benefit. Concomitant administration of potent inhibitors and inducers of CYP3A4 should be avoided since plasma levels of this CYP3A4- metabolized drug will be affected. Trabectedin is contraindicated in patients with a known hypersensitivity to trabectedin, concurrent serious or uncontrolled infection, or breast-feeding. Trabectedin should also not be administered in combination with yellow fever vaccine. Finally, there are strict criteria regarding absolute neutrophil count, platelet count, and renal and hepatic enzyme levels for permission to initiate or continue treatment with trabectedin.
ecteinascidin 743 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
ecteinascidin 743 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 157)Lieferanten
114899-77-3()Verwandte Suche:
- ecteinascidin 743
- (1'R,6R,6aR,7R,13S,14S,16R)-
- Trabectedin(Ecteinascidin 743,NSC-684766,ET-743, Yondelis)
- Ecteinascidine 743
- NSC 648766
- Trabectedin(Ecteinascidin 743,NSC-684766,ET-743)
- Trabectedin
Ecteinascidin
- Yondelis R ,Trabectedin
- NSC-684766
- Trabectedin (Ecteinascidin 743)
- PKVRCIRHQMSYJX-ZKZLGIKISA-N
- cteinascidin
- ECTEINASCIDIN 743; ET-743; ECTEINASCIDIN
- Trabectedin, >95%
- Trabectedin (Yondelis)
- Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)-
- ASMF Filed
- TrabectedinQ: What is
Trabectedin Q: What is the CAS Number of
Trabectedin Q: What is the storage condition of
Trabectedin Q: What are the applications of
Trabectedin
- Trabectedin
- ET-743
- Yondelis
- Ecteinascidin
- ecteinascidin 743,Trabectedin,ET 743
- ET 743,Ecteinascidin743,inhibit,ROS,Inhibitor,Trabectedin,backbone,Ecteinascidin-743,Cytotoxicity,tetrahydroisoquinoline,superoxides,ET743,DNA,Apoptosis,alkaloid,cell-cycle,anti-inflammatory,antitumor,Reactive Oxygen Species
- (1′R,6R,6aR,7R,13S,14S,16R)-5-(Acetyloxy)-3′,4′,6,6a,7,13,14,16-octahydro-6′,8,14-trihydroxy-7′,9-dimethoxy-4,10,23-trimethylspiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1′(2′H)-isoquinolin]-19-one
- 114899-77-3
- C39H43N3O11S
- Amines
- Heterocycles
- Intermediates & Fine Chemicals
- Pharmaceuticals
- API
- 114899-77-3
